The rapid development of new treatments for hepatitis C virus (HCV) has truly been astonishing over the last 3 years with the introduction of all oral direct-acting antivirals (DAAs). Multiple therapeutic regimens are now available for patients depending on viral genotype.1–6 Although no comparative studies exist between regimens, all have very similar overall sustained virologic response (SVR) rates of >95% in a broad range of patients, with the best response in genotype 1 compared with genotypes 2 and 3.